Edition:
United States

ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

37.53USD
11:10am EDT
Change (% chg)

$-0.14 (-0.37%)
Prev Close
$37.67
Open
$37.67
Day's High
$37.98
Day's Low
$37.29
Volume
141,005
Avg. Vol
1,431,357
52-wk High
$40.83
52-wk Low
$20.68

Latest Key Developments (Source: Significant Developments)

ACADIA Pharmaceuticals Q2 loss per share $0.55
Tuesday, 8 Aug 2017 04:38pm EDT 

Aug 8 (Reuters) - ACADIA Pharmaceuticals Inc :Q2 sales $30.5 million.Q2 loss per share $0.55.ACADIA Pharmaceuticals Inc - ‍expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million​.ACADIA Pharmaceuticals - ‍at June 30, 2017, co's cash, cash equivalents, investment securities totaled $417.3 million, versus $529.0 million at December 31, 2016​.  Full Article

Acadia pharmaceuticals Q2 loss per share $0.55
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Acadia Pharmaceuticals Inc :Acadia pharmaceuticals reports second quarter 2017 financial results.Q2 sales $30.5 million.Q2 loss per share $0.55.Sees fy 2017 sales $105 million to $115 million.Q2 revenue view $20 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.  Full Article

Acadia Pharmaceuticals reports Q1 revenue $15.3 million
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports first quarter 2017 financial results.Q1 revenue $15.3 million versus I/B/E/S view $15.2 million.Q1 loss per share $0.72.Q1 earnings per share view $-0.73 -- Thomson Reuters I/B/E/S.Acadia Pharmaceuticals Inc says plan to advance Alzheimer's disease psychosis (ad psychosis) program into phase III in second half of 2017.  Full Article

Acadia Pharmaceuticals Q4 loss per share $0.65
Tuesday, 28 Feb 2017 04:05pm EST 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016 . Q4 loss per share $0.65 .Q4 earnings per share view $-0.65 -- Thomson Reuters I/B/E/S.  Full Article

Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis
Tuesday, 20 Dec 2016 07:00am EST 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces positive top-line results from phase ii study of pimavanserin for alzheimer's disease psychosis . Pimavanserin met primary endpoint showing a statistically significant reduction in psychosis versus placebo .Pimavanserin was generally well tolerated.  Full Article

Acadia Pharmaceuticals initiates phase II trial of Pimavanserin
Tuesday, 15 Nov 2016 09:00am EST 

Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia.  Full Article

Acadia Pharmaceuticals announces proposed public offering of common stock
Monday, 8 Aug 2016 04:01pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals announces proposed public offering of common stock .Acadia Pharmaceuticals Inc says that it intends to offer and sell, subject to market and other conditions, $200 million of its common stock.  Full Article

Acadia Pharmaceuticals reports Q2 2016 financial results
Thursday, 4 Aug 2016 04:05pm EDT 

Acadia Pharmaceuticals Inc : Acadia Pharmaceuticals reports second quarter 2016 financial results .Qtrly loss per share $0.63.  Full Article

UK's CMA could accept undertakings on Acadia's Priory Group deal
Thursday, 28 Jul 2016 07:09am EDT 

UK's CMA : To look at Acadia's undertakings offer in relation to acquisition of Priory Group No 1 Ltd in detail . Considers that undertaking offered, or a modified version of it, might be accepted .Now has until 23 September to decide whether to accept undertaking, with possibility to extend this timeframe to 18 november.  Full Article

ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
Tuesday, 5 Jan 2016 04:05pm EST 

ACADIA Pharmaceuticals Inc:t intends to offer and sell, subject to market and other conditions, $300,000,000 of shares of its common stock in an underwritten public offering.There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering.ACADIA intends to grant the underwriters a 30-day option to purchase an additional $45,000,000 of shares of its common stock.  Full Article

Photo

Big-name U.S. hedge funds shed healthcare stocks during the rally in second-quarter

NEW YORK Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.